Breaking Finance News

Wedbush issued a report on Eiger Biopharmaceuticals Inc (NASDAQ:EIGR), bumping down its price target to $6.75 earlier today

Wedbush lowered the target price of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) to $6.75 indicating a possible downside of -0.05%.

Previously on 6/6/2017, Zacks Investment Research reported about Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) raised the target price from $0.00 to $7.75. At the time, this indicated a possible upside of 0.13%.

Yesterday Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) traded 6.19% higher at $7.07. The company’s 50-day moving average is $8.79 and its 200-day moving average is $8.65. The last stock close price is down 28.89% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 60,942 shares of the stock were exchanged, down from an average trading volume of 86,519

See Chart Below

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR)

Eiger Biopharmaceuticals Inc has a 52 week low of $6.10 and a 52 week high of $14.95 The company’s market cap is currently $0.

In addition to Wedbush reporting its target price, a total of 3 firms have reported on the stock. The consensus target price is $36.17 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Eiger Biopharmaceuticals Inc (NASDAQ:EIGR)

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.